Your browser doesn't support javascript.
loading
Outcomes of adolescents and young adults treated for brain and skull base tumors with pencil beam scanning proton therapy.
Lim, Pei S; Tran, Sébastien; Kroeze, Stephanie G C; Pica, Alessia; Hrbacek, Jan; Bachtiary, Barbara; Walser, Marc; Leiser, Dominic; Lomax, Antony J; Weber, Damien C.
  • Lim PS; Department of Radiation Oncology, University College London Hospitals, London, United Kingdom.
  • Tran S; Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.
  • Kroeze SGC; Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland.
  • Pica A; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Hrbacek J; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Bachtiary B; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Walser M; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Leiser D; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Lomax AJ; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
  • Weber DC; Department of Physics, ETH Zürich, Zürich, Switzerland.
Pediatr Blood Cancer ; 67(12): e28664, 2020 12.
Article en En | MEDLINE | ID: mdl-32881313
ABSTRACT

BACKGROUND:

The use of proton therapy (PT) in adolescents and young adults (AYAs) is becoming increasingly popular. This study aims to assess the outcomes and late toxicity consequences in AYAs (15-39 years) with brain/skull base tumors treated with pencil beam scanning proton therapy.

METHODS:

One hundred seventy six AYAs treated curatively at the Paul Scherrer Institute (PSI) were identified. Median age was 30 years (range 15-39) and median prescribed dose was 70.0 Gy (relative biological effectiveness [RBE]) (range 50.4-76.0). The most common tumors treated were chordomas/chondrosarcomas (61.4%), followed by gliomas (15.3%), and meningiomas (14.2%).

RESULTS:

After a median follow up of 66 months (range 12-236), 24 (13.6%) local only failures and one (0.6%) central nervous system (CNS) distant only failure were observed. The 6-year local control, distant progression-free survival, and overall survival were 83.2%, 97.4%, and 90.2%, respectively. The 6-year high-grade (≥grade [G] 3) PT-related late toxicity-free survival was 88.5%. Crude late toxicity rates were 26.2% G1, 37.8% G2, 12.2% G3, 0.6% G4, and 0.6% G5. The one G4 toxicity was a retinopathy and one G5 toxicity was a brainstem hemorrhage. The 6-year cumulative incidences for any late PT-related pituitary, ototoxicity, and neurotoxicity were 36.3%, 18.3%, and 25.6%; whilst high-grade (≥G3) ototoxicity and neurotoxicity were 3.4% and 2.9%, respectively. No secondary malignancies were observed. The rate of unemployment was 9.5% pre-PT, increasing to 23.8% post-PT. Sixty-two percent of survivors were working whilst 12.7% were in education post-PT.

CONCLUSIONS:

PT is an effective treatment for brain/skull base tumors in the AYA population with a reasonable late toxicity profile. Despite good clinical outcomes, around one in four AYA survivors are unemployed after treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Encefálicas / Neoplasias de la Base del Cráneo / Terapia de Protones Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Encefálicas / Neoplasias de la Base del Cráneo / Terapia de Protones Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article